Cancer Stocks That Are Advancing the Future of Oncology Care
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
XLO - Xilio Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$98.00
DETAILS
HIGH:
$98.00
LOW:
$98.00
MEDIAN:
$98.00
CONSENSUS:
$98.00
UPSIDE:
1087.88%
Stock News
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
Xilio Therapeutics, Inc. (XLO) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $2.52 per share a year ago.
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective May 1, 2026, the company granted a non-qualified stock options to purchase 1,982 shares of its common stock to one new employee under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Cheryl R. Blanchard, Ph.D. to the company's board of directors. The company also announced that Christina Rossi has stepped down from its board of directors, effective April 15, 2026.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
Oncology is evolving fast as immunotherapy, AI and targeted drugs expand treatment options, boost outcomes, and fuel long-term healthcare growth.
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will implement a 1-for-14 reverse stock split of the issued shares of the company's common stock, effective at 5:00 p.m.
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Xilio Therapeutics Announces Pricing of Underwritten Offering
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at a price to investors of $0.5349 per pre-funded warrant (the “pre-funded warrants”). Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. The offering is expected to close on or about February 13, 2026, subject to satisfaction of customary closing conditions. All of the pre-funded warrants are being offered by Xilio.